Table 7.
Prognostic value of clinicopathological variables in predicting disease free survival of 138 patients using Cox univariate and multivariate models.
| Variables | Cox Univariate analysis (DFS) | Cox multivariate analysis (DFS) | ||
|---|---|---|---|---|
| p-value | HR (95%CI) | p-value | HR (95%CI) | |
| Pre NAV | ||||
| Tumor stage (cT) | 0.010 | 1.139–2.555 | 0.057 | – |
| Ki-67 (<20/≥20) | 0.542 | 0.255–13.453 | ||
| p53 (+/−) | 0.973 | 0.52–1.883 | ||
| CK5/6 (+/−) | 0.950 | 0.538–1.937 | ||
| EGFR (+/−) | 0.875 | 0.453–2.533 | ||
| BLBC/NBLBC | 0.275 | 0.595–6.196 | ||
| Histological grades | 0.001 | 1.174–1.782 | 0.016 | 1.056–1.696 |
| Post NAC | ||||
| Ki-67 (<20/≥20) | 0.779 | 0.532–2.324 | ||
| p53 (+/−) | 0.813 | 0.456–1.851 | ||
| CK5/6 (+/−) | 0.036 | 1.06–5.337 | 0.041 | 1.035–5.381 |
| EGFR (+/−) | 0.177 | 0.748–4.853 | ||
| BLBC/NBLBC | 0.190 | 0.519–27.459 | ||
| ORR/NR | 0.0151 | 1.581–5.534 | 0.023 | 1.11–3.98 |
| ypT | <0.001 | 1.381–2.393 | 0.009 | 1.112–2.083 |
| ypN | <0.001 | 1.436–2.289 | 0.001 | 1.237–2.065 |
EGFR, epidermal growth factor receptor; CK5/6, cytokeratin5/6; ORR, overall response group; NR, no response group; NBLBC, non-basal-like breast cancer; BLBC, basal-like breast cancer; ypT, post neoadjuvant chemotherapy Tumor; ypN, post neoadjuvant chemotherapy Lymph note.